We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Cardiology

Cardiology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Harnessing Cardiac CT Radiomics of Epicardial Fat for Early Heart Failure Prediction
Cardiologycardiac CTEpicardial adipose tissue

Harnessing Cardiac CT Radiomics of Epicardial Fat for Early Heart Failure Prediction

By MedXY|Jul 4, 2026

Radiomic analysis of epicardial adipose tissue from routine cardiac CT scans enables robust, noninvasive early prediction of heart failure risk, enhancing conventional models and supporting precision prevention strategies.

Impact of Cerebral Small Vessel Disease on Functional Decline: Insights from the Bleeding With Antithrombotic Therapy 2 Study and Related Evidence
CardiologyFunctional DeclineLiệu pháp chống huyết khối

Impact of Cerebral Small Vessel Disease on Functional Decline: Insights from the Bleeding With Antithrombotic Therapy 2 Study and Related Evidence

By MedXY|Jul 3, 2026

Cerebral small vessel disease (SVD) significantly contributes to functional decline independently of bleeding or ischemic events during antithrombotic therapy, underscoring the need for targeted management strategies to address SVD burden i

Acoramidis and Kidney Function in Transthyretin Amyloid Cardiomyopathy: Clinical Implications and Hemodynamic Insights
Cardiologyacoramidisalbuminuria

Acoramidis and Kidney Function in Transthyretin Amyloid Cardiomyopathy: Clinical Implications and Hemodynamic Insights

By MedXY|Jul 3, 2026

Acoramidis stabilizes transthyretin and shows kidney-protective effects in transthyretin amyloid cardiomyopathy by reducing eGFR decline and albuminuria, with an initial reversible dip in kidney function associated with improved clinical ou

Economic Impact and Clinical Benefits of Quadruple Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Comprehensive Review
Cardiologycost offsetguideline-directed medical therapy

Economic Impact and Clinical Benefits of Quadruple Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Comprehensive Review

By MedXY|Jul 3, 2026

This review synthesizes evidence demonstrating that implementing full quadruple GDMT (ARNI, β-blockers, MRAs, SGLT2i) in HFrEF reduces hospitalization risks and healthcare costs, often yielding net savings despite medication expenses.

Enhancing Risk Prediction After TAVI: The COPD-Augmented R₂CHA₂DS₂-VA Score and Its Prognostic Value
Cardiologycardiovascular outcomesCOPD

Enhancing Risk Prediction After TAVI: The COPD-Augmented R₂CHA₂DS₂-VA Score and Its Prognostic Value

By MedXY|Jul 3, 2026

A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.

Switching from Warfarin to Direct Oral Anticoagulants in Frail Elderly Asian Patients with Atrial Fibrillation: Insights from a Korean Nationwide Study
CardiologyanticoagulationAsian Population

Switching from Warfarin to Direct Oral Anticoagulants in Frail Elderly Asian Patients with Atrial Fibrillation: Insights from a Korean Nationwide Study

By MedXY|Jul 3, 2026

In frail elderly Asian AF patients stable on warfarin, transitioning to DOACs increased risks of bleeding, thromboembolic events, and mortality, emphasizing cautious individualized management.

Ultra-Thin Sirolimus-Eluting Stents Show Noninferiority to Everolimus-Eluting Stents in Diabetic Multivessel CAD: Insights from TUXEDO-2 Trial
Cardiologycoronary artery diseaseDiabetes Mellitus

Ultra-Thin Sirolimus-Eluting Stents Show Noninferiority to Everolimus-Eluting Stents in Diabetic Multivessel CAD: Insights from TUXEDO-2 Trial

By MedXY|Jul 2, 2026

The TUXEDO-2 trial demonstrated that ultra-thin strut biodegradable polymer sirolimus-eluting stents are noninferior to durable polymer everolimus-eluting stents in diabetic patients with multivessel coronary artery disease at 1-year follow

Impact of Multidimensional Social Adversity on Mortality and Rehospitalization in People with HIV and Heart Failure
Cardiologyheart failureHIV

Impact of Multidimensional Social Adversity on Mortality and Rehospitalization in People with HIV and Heart Failure

By MedXY|Jul 2, 2026

This study explores how various social adversity domains affect mortality and rehospitalization risks in HIV-positive patients with heart failure, underscoring the importance of holistic social assessments for improving outcomes.

Cardiac Risk After Heart-Sparing Breast Radiotherapy: Emphasis on Left Anterior Descending Artery Dose Metrics
Cardiologybreast cancerCardiotoxicity

Cardiac Risk After Heart-Sparing Breast Radiotherapy: Emphasis on Left Anterior Descending Artery Dose Metrics

By MedXY|Jul 2, 2026

Emerging evidence indicates that radiation dose to the left anterior descending coronary artery better predicts cardiac events than whole-heart dose in breast radiotherapy, emphasizing the importance of LAD-based planning to reduce long-ter

Continuous Glucose Monitoring-Derived Time in Range Predicts Longitudinal Changes in Arterial Stiffness in Type 2 Diabetes
Cardiologycontinuous glucose monitoringpulse wave velocity

Continuous Glucose Monitoring-Derived Time in Range Predicts Longitudinal Changes in Arterial Stiffness in Type 2 Diabetes

By MedXY|Jul 1, 2026

This study demonstrates that continuous glucose monitoring-derived time in range (TIR) is independently associated with progression of arterial stiffness in type 2 diabetes, highlighting TIR as a valuable metric beyond HbA1c for cardiovascu

AAVrh.10hFXN Gene Therapy for Friedreich Ataxia Cardiomyopathy: Safety and Preliminary Efficacy in a Nonrandomized Clinical Trial
CardiologyAAVrh.10hFXNcardiomyopathy

AAVrh.10hFXN Gene Therapy for Friedreich Ataxia Cardiomyopathy: Safety and Preliminary Efficacy in a Nonrandomized Clinical Trial

By MedXY|Jul 1, 2026

This review synthesizes evidence from a pioneering nonrandomized trial demonstrating that intravenous AAVrh.10hFXN gene therapy is safe and may improve cardiac outcomes in Friedreich ataxia cardiomyopathy, highlighting translational advance

Beyond Granulomas: Unraveling Cardiac Sarcoidosis with Spatial Proteomics
Cardiologycardiac sarcoidosisgranuloma

Beyond Granulomas: Unraveling Cardiac Sarcoidosis with Spatial Proteomics

By MedXY|Jul 1, 2026

Spatial proteomics reveals immune and metabolic heterogeneity in cardiac sarcoidosis, identifying new diagnostic protein signatures beyond granulomatous lesions.

Decoding the Cardiovascular Risks of PM2.5 Components: Insights from a Half-Million Chinese Adults Cohort Study
Cardiologyair pollutioncardiovascular disease

Decoding the Cardiovascular Risks of PM2.5 Components: Insights from a Half-Million Chinese Adults Cohort Study

By MedXY|Jul 1, 2026

This large-scale study links specific PM2.5 components, especially chloride, black carbon, and sulfate, to increased long-term cardiovascular disease risk, emphasizing targeted pollution control for better heart health.

Pulsed Field Ablation Versus Sham Procedure in Atrial Fibrillation: Insights from the PFA-SHAM Randomized Clinical Trial
Cardiologyatrial fibrillationPulsed-field ablation

Pulsed Field Ablation Versus Sham Procedure in Atrial Fibrillation: Insights from the PFA-SHAM Randomized Clinical Trial

By MedXY|Jul 1, 2026

This sham-controlled trial demonstrates that pulsed field ablation significantly reduces atrial fibrillation recurrence, burden, and improves quality of life and psychological distress compared to sham treatment.

Left Atrial to Ventricular Volume Ratio: A Novel Imaging Biomarker Enhancing Detection of Atrial Cardiopathy and Stroke Risk
CardiologyAtrial Cardiopathycardiac imaging

Left Atrial to Ventricular Volume Ratio: A Novel Imaging Biomarker Enhancing Detection of Atrial Cardiopathy and Stroke Risk

By MedXY|Jun 28, 2026

The left atrial to ventricular volume ratio (LA:LV ratio) emerges as a superior marker over left atrial volume index (LAVi) for atrial cardiopathy, showing stronger association with ischemic stroke risk, cognitive decline, and atrial fibril

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Insights from the MAPLE-HCM Phase 3 Randomized Trial
CardiologyAficamtenexercise capacity

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Insights from the MAPLE-HCM Phase 3 Randomized Trial

By MedXY|Jun 28, 2026

The MAPLE-HCM trial demonstrates aficamten monotherapy significantly outperforms metoprolol in improving exercise capacity, hemodynamics, and patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM), supporting aficamten

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study
CardiologyAficamtenCardiac Myosin Inhibitor

Aficamten Demonstrates Sustained Benefits and Safety in Long-Term Management of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights from the FOREST-HCM Study

By MedXY|Jun 28, 2026

The FOREST-HCM long-term study confirms aficamten’s efficacy and safety in reducing left ventricular outflow tract obstruction and improving symptoms in obstructive hypertrophic cardiomyopathy over nearly one year of treatment.

Long-Term Success of Combined Myectomy and Secondary Mitral Chordal Cutting in Obstructive Hypertrophic Cardiomyopathy
CardiologyHypertrophic CardiomyopathyMitral Valve Chordae

Long-Term Success of Combined Myectomy and Secondary Mitral Chordal Cutting in Obstructive Hypertrophic Cardiomyopathy

By MedXY|Jun 28, 2026

This study demonstrates that septal myectomy combined with cutting of secondary mitral valve chordae delivers excellent long-term survival and symptom relief in obstructive hypertrophic cardiomyopathy patients unresponsive to medical therap

Inflammation as a Modifier of Lipoprotein(a)–Associated Cardiovascular Risk: Insights from the UK Biobank
CardiologyAortic Valve Stenosiscoronary artery disease

Inflammation as a Modifier of Lipoprotein(a)–Associated Cardiovascular Risk: Insights from the UK Biobank

By MedXY|Jun 27, 2026

Elevated lipoprotein(a) increases coronary artery disease risk, but this study reveals that inflammation—particularly IL-6 levels—modulates this risk, highlighting the importance of inflammatory biomarkers in cardiovascular risk assessment

Unveiling the Burden of Valvular Heart Disease Among Older Americans: Insights from the PREVUE-VALVE Study
Cardiologyechocardiographyolder adults

Unveiling the Burden of Valvular Heart Disease Among Older Americans: Insights from the PREVUE-VALVE Study

By MedXY|Jun 26, 2026

The PREVUE-VALVE study reveals a significant prevalence of moderate or greater valvular heart disease among U.S. adults aged 65-85, highlighting substantial public health implications and the value of decentralized echocardiographic screeni

Prev
14 / 25
1…1213141516…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles